

Q1 FY27 Quarterly Activities Report & Appendix 4C

Record core testing revenue, up 31% vs PCP; GI Navigator launched in Australia and the United Kingdom; cost base reset underway.

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a company at the forefront of microbiome diagnostics, is pleased to provide a summary of its activities for the quarter ended 30 September 2026.

Key Highlights

- **GI Navigator launched** on 7 October 2026 in Australia and the United Kingdom: a world-first full microbiome and gut test to help healthcare practitioners resolve complex gastrointestinal symptoms. More than 150 early access tests were ordered ahead of launch, and more than 400 practitioners joined the waitlist.
- **Record core test volume** of 6,527 tests, up 32% vs PCP and 3% QoQ, an annualised run rate of more than 26,000 tests.
- **Record Australian quarter** of 5,589 Microbiome Explorer tests, up 44% vs PCP, with ordering clinicians up 15% to 963 and tests per clinician up 25% to 5.8. New Australian pricing took effect on 1 September 2026, with list prices up 13–22%.
- **Microbiome Explorer 3.0 released**, including a new one-page report and Species in Marker, rolled out to practitioners in September.
- **Cost base reset:** annualised cash operating costs reduced by approximately \$5m, or over 20%, compared with FY26.⁷ Further annualised reductions of approximately \$3m are planned, which would take the total reduction to more than 30% of the FY26 cost base.
- **Funding and leadership:** after quarter end, Microba received firm commitments for a \$2.025 million placement (before costs), supported by substantial shareholder Sonic Healthcare, together with Perennial, Thorney and Microba directors. On 25 September 2026, Geoff Cockerill was appointed Interim Chief Executive Officer.
- **View this announcement on our Investor Hub:** <https://ir.microba.com/link/yVd9ar>

Financial Performance¹

- Record core testing revenue of \$2.57m, up 31% vs PCP and 2% QoQ, the 13th consecutive quarter of core testing growth, and now 75% of group revenue (Q1 FY26: 54%).
- Total revenue of \$3.44m, down 4% vs PCP after the exit of legacy and distributed products, and down 16% QoQ as Q4 FY26 included approximately \$0.4m of annual partner revenue recognition. Core testing and own-brand Invivo revenue grew 25% vs PCP. A late-September laboratory delay moved \$0.21m of revenue into October; excluding this and the Q4 partner revenue, revenue was broadly flat QoQ.
- Microbiome Explorer deferred revenue of \$1.99m at 30 September 2026, up 54% vs PCP.
- Cash receipts of \$4.27m, up 1% vs PCP and 8% QoQ, the highest quarterly receipts since the September 2024 quarter.
- Net operating cash outflow of \$3.80m, including approximately \$0.45m of one-off restructuring payments and \$0.34m of annual payments that fall in the first quarter. Normalised operating cash outflow of \$3.01m, down 5% QoQ.
- Cash and equivalents of \$3.87m at 30 September 2026.



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621



GI NAVIGATOR LAUNCH

On 7 October 2026, Microba launched GI Navigator in Australia and the United Kingdom. GI Navigator is a world-first full microbiome and gut test, designed to help healthcare practitioners resolve complex gastrointestinal symptoms. It focuses on complex or persistent GI symptoms, while Microbiome Explorer continues to be used across a broader range of systemic health issues, giving practitioners the choice of test that best suits each patient.

From a single at-home stool sample and a short online patient questionnaire, GI Navigator combines full microbiome mapping², patient presentation assessment, gut physiology and pathogen screening in one test. Results are interpreted by Microba's proprietary Clinical Logic Engine, drawing on more than 2,500 peer-reviewed studies, to give practitioners clear, prioritised suggested next steps for each patient.³

GI Navigator addresses an estimated 82 million patients who present each year with lower GI symptoms across seven major markets, around half of whom do not get a resolution through routine care.^{4,5} More than 150 tests were ordered through the early access programme ahead of launch (Q1 FY27: 116), and more than 400 practitioners joined the waitlist, including more than 150 who had not previously ordered a Microba test. GI Navigator is priced at \$549 in Australia and £399 in the United Kingdom and is processed through Microba's existing laboratory and digital platform. Take-up in the first week of launch was strong, and Microba will separately report GI Navigator sales from the December 2026 quarter.

INTRODUCING GI Navigator



A new era for clinical gut testing is here.

DIAGNOSTICS

Microbiome Explorer™ – Australia

Microbiome Explorer delivered another record quarter in Australia, with 5,589 tests sold, up 44% vs PCP and 5% QoQ. Ordering clinicians rose 15% vs PCP to 963, and tests per clinician grew 25% to 5.8. New Australian Microbiome Explorer product pricing took effect on 1 September 2026: Essentials \$449 (previously \$369), Extended \$479 (previously \$425) and Comprehensive \$549 (previously \$485). August 2026 was the highest month on record for Australian orders, around 20% above the previous record set in June 2026, and 31 August



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

was the highest single day on record, with over 200 orders in a single day. Microba also held its first Clinical Conversations Roadshow, with in-person clinician education events in Sydney, Melbourne, Brisbane and Perth; most events sold out.

Australia	Q1 FY27	vs Q1 FY26 (PCP)	vs Q4 FY26 (QoQ)
Microbiome Explorer tests sold	5,589	3,884, up 44%	5,311, up 5%
Ordering clinicians	963	837, up 15%	901, up 7%
MetaPanel™ tests sold	213	264, down 19%	225, down 5%

Microbiome Explorer™ – United Kingdom

In the United Kingdom, 725 Microbiome Explorer tests were sold, down 7% vs PCP and 12% QoQ, during a quieter than anticipated UK summer holiday period. Larger clinic accounts are also taking longer than anticipated to secure, onboard and build to their full ordering potential. UK core testing revenue grew 19% vs PCP to \$0.55 million. Lifting UK sales is an immediate priority, and the Company has also taken decisive actions aimed at increasing sales, as well as further cost reduction actions as outlined in the Financials section.

United Kingdom	Q1 FY27	vs Q1 FY26 (PCP)	vs Q4 FY26 (QoQ)
Microbiome Explorer tests sold	725	783, down 7%	825, down 12%
Ordering clinicians	287	299, down 4%	313, down 8%

Microbiome Explorer 3.0

Microbiome Explorer 3.0 was rolled out to practitioners in Australia and the United Kingdom in September. The release brings the full report onto a single page led by a concise Report summary; introduces Species in Marker, which shows the species contributing to every functional microbiome marker; adds 26 new evidence-graded diet and lifestyle interventions; and refines healthy reference ranges using a larger Microba Healthy Cohort.

SUPPLEMENTS

Invivo own-brand supplement revenue was \$0.70 million, up 6% vs PCP, with unit sales up 18%. Growth was led by direct-to-consumer channels, particularly Amazon, and the Invivo subscription base grew to approximately 1,350 subscribers, from more than 1,000 at 30 June 2026. During the quarter Invivo launched in Holland & Barrett, completed set-up for launch into Germany and received its first European distributor order, launched four new product bundles, introduced a volume-based partner programme to standardise distributor pricing, and began cross-selling to UK clinics that already order Microba diagnostic tests.

Invivo completed its exit from distributing third-party Designs For Health (DFH) products in Q4 FY26. Residual DFH revenue of \$0.02 million (Q1 FY26: \$0.36 million) reflects the sell-down of remaining stock. As announced today, Microba plans to commence an advisory process for a potential sale of the Invivo Supplements business, following expressions of interest.

Supplements	Q1 FY27	vs Q1 FY26 (PCP)	vs Q4 FY26 (QoQ)
Invivo supplements	\$0.70m	\$0.66m, up 6%	\$0.75m, down 7%
Distributed supplements (DFH)	\$0.02m	\$0.36m, down 94%	\$0.12m, down 83%



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

FINANCIALS¹

Total revenue was \$3.44 million, down 4% vs PCP following the exit of legacy and distributed products, and down 16% QoQ as Q4 FY26 included approximately \$0.4 million of annual revenue recognition for unused committed testing volumes from international testing partners. Core testing revenue grew 31% vs PCP to a record \$2.57 million, and a late-September laboratory delay moved \$0.21 million of revenue into October. Excluding these two items, total revenue was broadly flat QoQ. Cash receipts were \$4.27 million, up 1% vs PCP and 8% QoQ. Net cash used in operating activities was \$3.80 million (Q4 FY26: \$3.43 million; Q1 FY26: \$4.56 million), including approximately \$0.45 million of one-off restructuring payments and \$0.34 million of annual payments that fall in the first quarter (insurance, ASX listing fees, software subscriptions and annual workers compensation premiums). Excluding these items, normalised operating cash outflow was \$3.01 million⁶, down 5% QoQ.

Cost reduction. Since June 2026, Microba has reduced its annualised cash operating costs by approximately \$5 million, or over 20%, compared with FY26.⁷ Q1 FY27 is the first quarter to reflect these reductions, with staff costs excluding restructuring down 20% vs PCP; the full benefit is not yet visible due to employment notice periods which took place during the quarter. Restructuring payments for the current programme total approximately \$0.72 million to date. Following slower-than-expected revenue growth in the United Kingdom, Microba plans further annualised reductions of approximately \$3 million, which would take the total reduction to more than 30% of the FY26 cost base. These focus on property consolidation, a simpler leadership and organisational structure (including a smaller Board), not backfilling vacant roles, and lower contractor, marketing, software and overhead costs.

Cash payments (\$m)	Q1 FY27	Q1 FY26	vs PCP	Q4 FY26	QoQ
Staff costs*	3.56	4.57	-22%	3.50	+2%
Staff costs excluding restructuring	3.11	3.91	-20%	3.23	-4%
Product manufacturing and operating costs*	2.24	1.91	+17%	1.83	+22%
Administration and corporate costs*	1.65	1.65	0%	1.08	+53%
Advertising and marketing	0.52	0.31	+68%	0.76	-32%
Research and development	0.11	0.32	-66%	0.28	-61%
Net cash used in operating activities	3.80	4.56	-17%	3.43	+11%
Normalised operating cash outflow⁶	3.01	-	-	3.16	-5%
Combined operating and investing outflows	4.53	5.58	-19%	4.46	+2%

* Includes one-off items material to the comparison. Staff costs including restructuring payments (Q1 FY27: \$0.45m; Q4 FY26: \$0.27m; Q1 FY26: \$0.66m). Product manufacturing and operating costs including the July settlement of laboratory inventory invoices held at 30 June, including a bulk sequencing reagent purchase of approximately \$0.50m. Administration and corporate costs including annual renewals of approximately \$0.27m and legal costs of approximately \$0.14m.

Capital position. Cash and equivalents were \$3.87 million at 30 September 2026. After quarter end, as announced today, Microba received firm commitments for a \$2.025 million placement (before costs) at \$0.04 per share, supported by substantial shareholder Sonic Healthcare, together with Perennial, Thorney and Microba directors. Tranche 1 of \$1.025 million is expected to settle on 26 October 2026; Tranche 2 of \$1.0 million is subject to Microba shareholder approval and Genetic Signatures shareholders approving the proposed merger. See item 8.6 of the attached Appendix 4C.

Corporate

On 22 September 2026, Microba and Genetic Signatures Limited (ASX: GSS) announced a proposed merger. The board of the combined group will comprise six directors, three nominated by each company, and, as announced today, longstanding Microba directors Professor Ian Frazer AC and Professor Gene Tyson have agreed to step down from the Microba Board effective Wednesday 21 October 2026. On 25 September 2026, Geoff Cockerill was appointed Interim Chief Executive Officer.



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

In accordance with Listing Rule 4.7C, payments to related parties and their associates included in item 6.1 of the Appendix 4C totalled \$106,464, comprising director fees and consulting fees paid to a director.

Commenting on the quarter, Microba's Interim Chief Executive Officer, Geoff Cockerill, said:

"Microba has delivered another record quarter in Australia, and with GI Navigator now launched we have a second differentiated test in market. Our priorities are clear, convert strong clinician demand into revenue, lift performance in the United Kingdom, complete the optimisation of our cost base, and progress the proposed merger with Genetic Signatures. I thank the team for their commitment through a period of significant change."

- End -

This announcement has been authorised for release by the Board of Directors.

¹ Financials are preliminary and unaudited. ² 100% coverage of all gut microbial species described in Almeida et al. 2021, Nature Biotechnology, along with additional species, including eukaryotes. ³ GI Navigator is for use by healthcare practitioners as a clinical decision support tool. Suggested actions are intended to inform clinical management, not replace the judgement of the treating healthcare professional. ⁴ Assessment completed with Boston-based MedTech specialist consultancy Veranex Inc. Assessment analysed US Medicare claims for target patient populations, extrapolated Private and Medicaid numbers, populations and prevalence adjusted for key global markets outside of the US including Germany, Italy, Spain, France, United Kingdom and Australia. ⁵ Gordon, J., Miller, G., & Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family Physician, 44(9), 621-623. ⁶ Normalised figures are unaudited, non-IFRS measures, reconciled to Appendix 4C item 1.9 (\$3.80 million less \$0.45 million restructuring and \$0.34 million annual first-quarter payments). ⁷ Cash operating costs exclude cost of goods sold (product manufacturing and operating costs), restructuring and annual payments. Annualised figure is September 2026 payments x 12, compared with FY26 on the same basis. Unaudited, non-IFRS and not a forecast.

Forward-looking statements

This announcement contains certain "forward-looking statements", including statements about planned cost reductions, the expected settlement of the placement, the proposed merger with Genetic Signatures, the potential sale of the Invivo Supplements business and Microba's future operations. The words "expect", "anticipate", "estimate", "intend", "believe", "should", "could", "may", "will", "plan" and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Microba, its directors and management.

Forward-looking statements are provided as a general guide only and are not guarantees of future performance. Actual results, performance or achievements may differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects or statements in relation to future matters. Forward-looking statements are based on information available to Microba as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of Microba, its representatives or advisers undertakes any obligation to update them.

For further information, please contact:

Investor / Media Relations

investor@microba.com

<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba – Expect better. www.microba.com



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Microba Life Sciences Limited, and controlled entities

ABN

82 617 096 652

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers		4,271	4,271
1.2 Payments for			
(a) research and development		(110)	(110)
(b) product manufacturing and operating costs		(2,244)	(2,244)
(c) advertising and marketing		(516)	(516)
(d) leased assets		-	-
(e) staff costs		(3,564)	(3,564)
(f) administration and corporate costs		(1,651)	(1,651)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		23	23
1.5 Interest and other costs of finance paid		(10)	(10)
1.6 Income taxes paid		-	-
1.7 Government grants and tax incentives		-	-
1.8 Other (provide details if material)		-	-
1.9 Net cash from / (used in) operating activities		(3,801)	(3,801)
2. Cash flows from investing activities			
2.1 Payments to acquire or for:			
(a) entities		-	-
(b) businesses		-	-
(c) property, plant and equipment		(4)	(4)
(d) investments		-	-
(e) intellectual property		(725)	(725)
(f) other non-current assets		-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(729)	(729)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	830	830
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(51)	(51)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(48)	(48)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Payment for principal portion of lease liabilities)	(265)	(265)
3.10	Net cash from / (used in) financing activities	466	466

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	7,949	7,949
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,801)	(3,801)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(729)	(729)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	466	466
4.5	Effect of movement in exchange rates on cash held	(19)	(19)
4.6	Cash and cash equivalents at end of period	3,866	3,866

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,866	7,949
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,866	7,949

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(106)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: Payments included in item 6.1 above comprise director fees paid to directors of Microba Life Sciences Limited and consulting fees paid to a director during the period.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (Equipment & R&D Loan)	2,734	2,734
7.4	Total financing facilities	2,734	2,734
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. NovaSeqX Plus Funding Agreement: A funding arrangement with Westpac to finance the Group's Illumina NovaSeqX Plus DNA sequencing machine. The loan of \$629k was funded on 30 March 2026 and is repayable over 36 equal monthly instalments at a fixed interest rate of 7.39%. The loan is secured against the machine and matures on 31 March 2029. The balance outstanding at 30 September 2026 was \$515k. R&D Loan Advance Agreement: A \$2.05m secured funding arrangement with Radium Capital, under which the Group's R&D tax refund for the FY26 income year has been advanced. The facility is fully drawn (\$897k received on 27 March 2026 and \$1,149k on 2 April 2026). Interest is charged at a fixed rate of 16.00% per annum and capitalised monthly, and the balance including capitalised interest at 30 September 2026 was \$2,219k. The funding is secured against the Group's present and future right, title and interest in the R&D tax refund, and is repayable upon receipt of the FY26 R&D tax refund, with a maturity date of 31 January 2027.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,801)
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,866
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	3,866
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	1.02
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

No. The Group expects its underlying net operating cash outflows to reduce from the September quarter level. The September quarter outflow of \$3.80 million included approximately \$0.45 million of one-off restructuring and termination payments and approximately \$0.34 million of annual payments that fall in the first quarter of each financial year (insurance premiums, ASX listing fees, software subscriptions and workers compensation premiums). It also included the July settlement of approximately \$0.50 million of laboratory inventory invoices held at 30 June 2026, including a bulk purchase of sequencing reagents.

Cost reductions implemented since June 2026 have reduced the Group's annualised cash operating costs by approximately \$5 million, or over 20%, compared with FY26. The full benefit was not reflected in the September quarter, as employment notice periods ran through the quarter. Following slower-than-expected revenue growth in the United Kingdom, the Group plans further annualised cost reductions of approximately \$3 million, which would take the total reduction to more than 30% of the FY26 cost base.

Quarterly outflows may vary with the timing of one-off costs associated with the further cost reductions and with seasonally lower customer receipts over the December holiday period.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Yes. On 20 October 2026, the Company announced that it had received firm commitments to raise \$2.025 million (before costs) through a two-tranche placement at \$0.04 per share, supported by substantial shareholder Sonic Healthcare, together with Perennial, Thorney and Microba directors:

(a) Tranche 1 (\$1.025 million) will be issued under the Company's existing placement capacity under Listing Rule 7.1 and is expected to settle on 26 October 2026. Given the firm commitments received from existing substantial shareholders, the Company expects Tranche 1 to complete; and

(b) Tranche 2 (\$1.0 million, including \$75,000 from Microba directors) is subject to Microba shareholder approval at a general meeting expected to be held in December 2026 and to Genetic Signatures shareholders approving the proposed merger. There is no certainty that these conditions will be satisfied.

The Group's R&D Tax Incentive facility with Radium Capital (\$2.22 million at 30 September 2026, including capitalised interest) is secured against, and repayable from, the FY26 R&D Tax Incentive refund, which the Group expects to receive in the December 2026 quarter. The Company is also commencing an advisory process for a potential sale of its UK-based Invivo Supplements business, which, if completed, may provide additional funding. There is no certainty that this process will result in a transaction.

The Board will continue to assess the Group's funding requirements, including in the context of the proposed merger with Genetic Signatures, and will consider further funding options if required.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Yes. The Group expects to be able to continue its operations and to meet its business objectives on the basis that:

(a) Tranche 1 of the placement (\$1.025 million before costs) is expected to settle on 26 October 2026, with a further \$1.0 million under Tranche 2 subject to the conditions outlined in 8.6.2;

(b) the September quarter outflows included approximately \$0.79 million of one-off restructuring payments and annual payments that fall in the first quarter of each financial year;

(c) the cost reductions implemented since June 2026, together with the further annualised reductions of approximately \$3 million now planned, are expected to reduce net operating cash outflows;

(d) the Radium Capital facility is repayable from the FY26 R&D Tax Incentive refund; and

(e) core testing revenue continues to grow, with record core testing revenue of \$2.57 million in the September quarter, up 31% on the prior corresponding period, and GI Navigator launched in Australia and the United Kingdom in October 2026.

The Board continues to monitor the Group's cash position closely.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **20 October 2026**

Authorised by: **The Board of Directors**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.